Literature DB >> 30632919

Inflammatory bowel diseases and primary immunodeficiency diseases.

Hirokazu Kanegane1.   

Abstract

Recent advances in molecular biology have provided important insights into the genetic background of various inflammatory diseases. In particular, genome-wide association studies of inflammatory diseases have revealed genetic loci that play critical roles in the pathology of inflammation. Whole-exome and whole-genome sequencing analyses have also identified more than 300 causative genes for primary immunodeficiency diseases (PIDs). Some genetic loci that are associated with inflammatory diseases are mutated in PIDs, suggesting close relationships between inflammation and PIDs. Inflammatory diseases for which genetic associations have been described include inflammatory bowel disease (IBD), multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus, and systemic lupus erythematosus. Herein, I discuss about the genetic interactions between IBD and PIDs.

Entities:  

Keywords:  Inflammation; inflammatory bowel disease (IBD); monogenic IBD; polygenic IBD; primary immunodeficiency diseases

Year:  2019        PMID: 30632919     DOI: 10.1080/25785826.2018.1556025

Source DB:  PubMed          Journal:  Immunol Med        ISSN: 2578-5826


  3 in total

1.  Infantile Inflammatory Bowel Disease in a Three-Month-Old-Boy.

Authors:  Chie Iida; Ako Tatsumi; Hisanori Fujino; Kaori Anzai; Shinichi Sumimoto
Journal:  Cureus       Date:  2021-01-16

Review 2.  Linking Human Betaretrovirus with Autoimmunity and Liver Disease in Patients with Primary Biliary Cholangitis.

Authors:  Hussain Syed; Tara Penner; Andrew L Mason
Journal:  Viruses       Date:  2022-08-31       Impact factor: 5.818

3.  X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic.

Authors:  Tao Xu; Qin Zhao; Wenyan Li; Xuemei Chen; Xiuhong Xue; Zhi Chen; Xiao Du; Xiaoming Bai; Qian Zhao; Lina Zhou; Xuemei Tang; Xi Yang; Hirokazu Kanegane; Xiaodong Zhao
Journal:  Eur J Pediatr       Date:  2019-11-21       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.